Second Generation Direct-Antivirals for HCV in the Real World

January 17, 2018

Clinical trials of second generation direct-acting antivirals in HCV show high cure rates. But do those rates reflect real life?

What are HCV cure rates with second-generation direct-acting antivirals in difficult-to-treat populations, such as those with liver transplant or HIV coinfection?

References:

1. Afdhal N, Zeuzem S, Kwo P, et al.; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. NEJM. 2014;370:1889-1898.2.Kowdley KV, Gordon SC, Reddy KR, et al.; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. NEJM. 2014;370:1879-88.3. Afdhal N, Reddy KR, Nelson DR, et al.; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. NEJM. 2014;370:1483-1493.4. Ferenci P, Bernstein D, Lalezari J, et al. PEARL-III Study; PEARL-IV Study. ABT-450/rombitasvir and dasabuvir with or without ribavirin for HCV. NEJM. 2014;370:1983-19895. Aspinall AI, Shaheen AA, Kochaksaraei GS, et al. Real-world treatment of hepatitis C with second-generation direct-acting antivirals: initial results from a multicentre Canadian retrospective cohort of diverse patients. CMAJ Open. 2018 Jan 5;6(1):E12-E18. doi: 10.9778/cmajo.20170059.